Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Neurocrit Care. 2020 Apr;32(2):407-418. doi: 10.1007/s12028-019-00898-y.
With increasing use of direct oral anticoagulants (DOACs) and availability of new reversal agents, the risk of traumatic intracranial hemorrhage (tICH) requires better understanding. We compared hemorrhage expansion rates, mortality, and morbidity following tICH in patients treated with vitamin k antagonists (VKA: warfarin) and DOACs (apixaban, rivaroxaban, dabigatran).
Retrospective chart review of patients from 2010 to 2017 was performed to identify patients with imaging diagnosis of acute traumatic intraparenchymal, subdural, subarachnoid, and epidural hemorrhage with preadmission use of DOACs or VKAs. We identified 39 patients on DOACs and 97 patients on VKAs. Demographic information, comorbidities, hemorrhage size, and expansion over time, as well as discharge disposition and Glasgow Outcome Scale (GOS) were collected. Primary outcome was development of new or enlargement of tICH within the first 48 h of initial CT imaging.
Of 136 patients with mean (SD) age 78.7 (13.2) years, most common tICH subtype was subdural hematoma (N = 102/136; 75%), and most common mechanism was a fall (N = 130/136; 95.6%). Majority of patients in the DOAC group did not receive reversal agents (66.7%). Hemorrhage expansion or new hemorrhage occurred in 11.1% in DOAC group vs. 14.6% in VKA group (p = 0.77) at a median of 8 and 11 h from initial ED admission, respectively (p = 0.82). Patients in the DOAC group compared to VKA group had higher median discharge GOS (4 vs. 3 respectively, p = 0.03), higher percentage of patients with good outcome (GOS 4-5, 66.7% vs. 40.2% respectively, p = 0.005), and higher rate of discharge to home or rehabilitation (p = 0.04).
We report anticoagulation-associated tICH outcomes predominantly due to fall-related subdural hematomas. Patients on DOACs had lower tICH expansion rates although not statistically significantly different from VKA-treated patients. DOAC-treated patients had favorable outcomes versus VKA group following tICH despite low use of reversal strategies. DOAC use may be a safer alternative to VKA in patients at risk of traumatic brain hemorrhage.
随着直接口服抗凝剂(DOAC)的使用增加和新的逆转剂的出现,创伤性颅内出血(tICH)的风险需要更好地了解。我们比较了接受维生素 K 拮抗剂(VKA:华法林)和 DOAC(阿哌沙班、利伐沙班、达比加群)治疗的患者发生 tICH 后的出血扩展率、死亡率和发病率。
对 2010 年至 2017 年的患者进行回顾性图表审查,以确定影像学诊断为急性创伤性脑实质、硬膜下、蛛网膜下腔和硬膜外出血的患者,并在入院前使用 DOAC 或 VKA。我们确定了 39 名 DOAC 患者和 97 名 VKA 患者。收集人口统计学信息、合并症、出血大小以及随时间的扩展情况,以及出院情况和格拉斯哥结果量表(GOS)。主要结局是在初始 CT 成像后的前 48 小时内发生新的或扩大的 tICH。
在 136 名平均(SD)年龄为 78.7(13.2)岁的患者中,最常见的 tICH 类型是硬膜下血肿(N=102/136;75%),最常见的机制是跌倒(N=130/136;95.6%)。DOAC 组中大多数患者未接受逆转剂(66.7%)。DOAC 组的出血扩展或新出血发生率为 11.1%,VKA 组为 14.6%(p=0.77),中位数分别为入院后 8 小时和 11 小时(p=0.82)。与 VKA 组相比,DOAC 组的中位出院 GOS 更高(分别为 4 分和 3 分,p=0.03),良好结局(GOS 4-5)的患者比例更高(分别为 66.7%和 40.2%,p=0.005),出院回家或康复的比例更高(p=0.04)。
我们报告了主要因跌倒相关硬膜下血肿引起的抗凝相关 tICH 结果。尽管与接受 VKA 治疗的患者相比,DOAC 组的 tICH 扩展率没有统计学上的显著差异,但 DOAC 组的扩展率较低。尽管逆转策略的使用较低,但 DOAC 治疗的患者在发生 tICH 后与 VKA 组相比有更好的结局。在有创伤性脑出血风险的患者中,DOAC 可能是 VKA 的更安全替代方案。